Astrazeneca (AZN) Research & Development (2016 - 2026)

Astrazeneca has reported Research & Development over the past 16 years, most recently at -$3.5 billion for Q1 2026.

For Q1 2026, Research & Development fell 10.54% year-over-year to -$3.5 billion; the TTM value through Mar 2026 reached -$14.6 billion, down 4.34%, while the annual FY2025 figure was $14.2 billion, 4.78% up from the prior year.
Research & Development for Q1 2026 was -$3.5 billion at Astrazeneca, up from -$3.9 billion in the prior quarter.
Over five years, Research & Development peaked at -$2.1 billion in Q1 2022 and troughed at -$4.7 billion in Q4 2024.
A 5-year average of -$3.1 billion and a median of -$3.0 billion in 2024 define the central range for Research & Development.
On a YoY basis, Research & Development climbed as much as 31.91% in 2022 and fell as far as 606.29% in 2022.
Year by year, Research & Development stood at -$2.6 billion in 2022, then decreased by 17.07% to -$3.1 billion in 2023, then plummeted by 52.2% to -$4.7 billion in 2024, then increased by 17.43% to -$3.9 billion in 2025, then increased by 9.58% to -$3.5 billion in 2026.
Business Quant data shows Research & Development for AZN at -$3.5 billion in Q1 2026, -$3.9 billion in Q4 2025, and -$3.7 billion in Q3 2025.

Peer Comparison